| oxaliplatin / Generic mfg. |
NCT00263055: MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV |
|
|
| Completed | 4 | | RoW | oxaliplatin | Sanofi | Colonic Neoplasms | 06/05 | | | |
NCT00129870: CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer |
|
|
| Terminated | 4 | 180 | US | oxaliplatin | Sanofi | Colorectal Cancer | | 12/07 | | |
NCT00577031 / 2007-004969-18: OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. |
|
|
| Completed | 4 | 205 | Europe | bevacizumab [Avastin], Oxaliplatin, Xeloda | Hoffmann-La Roche | Colorectal Cancer | 08/11 | 08/11 | | |
|
NCT01468623: Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 |
|
|
| Terminated | 4 | 51 | US | Pharmacokinetic 5-FU dose adjustment using OnDose® assay, OnDose®, Standard of care | Myriad Genetic Laboratories, Inc. | Colorectal Cancer, Metastatic | 08/12 | 08/12 | | |
ASCENT, NCT01588990: A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer |
|
|
| Completed | 4 | 128 | RoW | Oxaliplatin, Capecitabine, Bevacizumab, Avastin, RO4876646, Leucovorin, 5-Fluouracil, Irinotecan | Hoffmann-La Roche | Colorectal Neoplasms | 09/16 | 09/16 | | |
